The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Aptamer–nanoparticle complexes as powerful diagnostic and therapeutic tools
Open accessAbstract
Correct diagnosis and successful therapy are extremely important to enjoy a healthy life when suffering from a disease. To achieve these aims, various cutting-edge technologies have been designed and fabricated to diagnose and treat specific diseases. Among these technologies, aptamer–nanomaterial hybrids have received considerable attention from scientists and doctors because they have numerous advantages over other methods, such as good biocompatibility, low immunogenicity and controllable selectivity. In particular, aptamers, oligonucleic acids or peptides that bind to a specific target molecule, are regarded as outstanding biomolecules. In this review, several screening techniques for aptamers, also called systematic evolution of ligands by exponential enrichment (SELEX) methods, are introduced, and diagnostic and therapeutic aptamer applications are also presented. Furthermore, we describe diverse aptamer–nanomaterial conjugate designs and their applications for diagnosis and therapy. A wide variety ofnanoparticle complexes that target specific biomolecules are revolutionizing disease diagnostics and therapies. Hunho Jo and Changill Ban at Pohang University of Science and Technology, South Korea, reviewed recent advances into the medical uses of aptamerscomplexed with nanoparticles. Aptamers arepeptides or small sections of DNA or RNA that can target and bind to specific chemicals in the body. In a complex, they effectively act as guides escorting nanoparticles to the places where they are needed. For example, aptamers can lead fluorescent nanoparticles to cancer cells to ensure clear imaging and diagnosis of tumors. The authors describe several promising aptamer-nanoparticle complexes, including probes for detecting cocaine and diagnosing breast cancer,as well asa drug delivery system that targets specific brain cells and may provide a therapy for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aptamers selected for higher-affinity binding are not more specific for the target ligand
Carothers, J. M., Oestreich, S. C., & Szostak, J. W. (2006) · Journal of the American Chemical Society · doi:10.1021/ja060952q · Cited by 132
Jo, H., Youn, H., Lee, S., & Ban, C. (2014) · J. Mater. Chem. B · doi:10.1039/c4tb00643g · Cited by 49
Self-citation
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019) · Cancers · doi:10.3390/cancers11050640 · Cited by 726
Applications of nanoparticles in biomedical imaging
Han, X., Xu, K., Taratula, O., & Farsad, K. (2019) · Nanoscale · doi:10.1039/c8nr07769j · Cited by 637
Wang, T., Chen, C., Larcher, L. M., Barrero, R. A., & Veedu, R. N. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.001 · Cited by 525
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Metadata
- Authors
- Jo, H., & Ban, C.
- Venue
- Experimental & Molecular Medicine
- Published
- 2016-05-06
- Volume
- 48
- Issue
- 5
- Pages
- e230-e230
- ISSN
- 1226-3613 (ISSN-L)
- 2092-6413
- OpenAlex
- W2346894235
- Cited by
- 188
- References
- 2
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aptamer–nanoparticle complexes as powerful diagnostic and therapeutic tools. https://app.cochat.ai/papers/10.1038/emm.2016.44
- The paper
- Jo, H., & Ban, C. (2016). Aptamer–nanoparticle complexes as powerful diagnostic and therapeutic tools. Experimental & Molecular Medicine. https://doi.org/10.1038/emm.2016.44
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.